Strategic partnerships OmniAb has recent collaboration activity with Lilly and Eli Lilly on ion channel programs and milestone-based partnerships, indicating a strong receptivity to co-discovery deals and potential expansion into therapeutic modalities that leverage their antibody repertoires.

Expanded discovery The OmniAb platform focuses on diverse antibody repertoires and high-throughput screening, suggesting opportunities to position as a preferred partner for pharma companies seeking rapid lead identification and next-generation antibody therapeutics.

Financial health signals Revenue trajectory and recent funding indicate readiness to scale collaboration programs; use this to propose larger, multi-program deals or milestone-heavy collaborations with upfront value aligned to growth objectives.

Leadership momentum Appointment of a new COO and recognition as a top small-cap growth stock reflect operational maturation and strategic execution capability, making a case for enterprise-wide collaborations and longer-term R&D partnerships.

Clinical and modality fit Active development in bispecific antibodies and potential ion channel programs align with high-value therapeutic areas; target pharma players pursuing oncology, infectious disease, and rare disease indications that benefit from diverse discovery platforms.